{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.8","upperLimit":"33.3","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"DOR is defined as the time from response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died. DOR was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All Phase II participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.","id":"OG000","title":"All Phase II Participants"}],"paramType":"MEDIAN","populationDescription":"All Phase II participants with measureable disease present at baseline and received at least one dose of the study drug were evaluable for DOR.","reportingStatus":"POSTED","timeFrame":"DIsease was assessed to document response every cycle on treatment and post-treatment every 12 weeks until progression.","title":"Duration of Response (DOR) [Phase II]","type":"SECONDARY","unitOfMeasure":"Months"}